- doing almost $0.25 trillion of TPV
- close to 90 million active accounts of (55 million active monthly accounts)
- driving over $100 million of revenue every month
Dan Schulman, CEO
➡️ A run rate revenue of $1.2B, i.e. 33% higher that 2021 revenue c$900M
2/4 - creating teen accounts -> addressable market for Venmo by some 20 million or 30 million incremental people.
- looking at international expansion there
Dan Schulman, CEO
➡️ International expansion could be huge. Any incremental increase in TAM (teen accounts) is a bonus
3/4 “then obviously, we've got Pay with Venmo, Amazon. Amazon is 30% of U.S. e-commerce-ish, think about the number of merchants that we would have to sign up here in the U.S. to get that same scale for Pay with Venmo, it would be multiple, multiple millions.” Dan Schulman, CEO
4/4 ➡️ Self explanatory and was one of the significant opportunities we noted in our deep dive. It shall be noted that $PYPL and $AMZN are working on the final technical issues.
Further to our recent review of $ZM Q2’23 and the pullback in price we decided to proceed with a valuation estimate. Our results and assumptions 👇
2/ Revenue 10.3% GAGR, is a result of 18.3% CAGR for the enterprise business and 0.2% for the online business.
Enterprise growth was gradually decreased from 24.6% in FY’23 to 15%.
For the online we assumed that revenues will flatten in FY’24 and return to growth thereafter.
3/ Average projected EBITDA margin of 13.4% and terminal EBITDA margin of 18%.
EBITDA margins are lower than FY’21 and FY’22 of 26% and 29%, respectively due to the increased investments in R&D and S&M to support new products and the RSU top-up programs.
1/7
We released our company snapshot at @SubstackInc on $VRTX, a biotech company which is a leader in the treatment of Cystic Fibrosis.
Snapshot Summary ⬇
2/7
- $VRTX is a dominant leader in Cystic Fibrosis with its commercial drugs generating $7.6 billion in revenue during fiscal 2021.
- Its blockbuster drug TRIKAFTA/KAFTRIO can address 90% of all mutations, has high efficacy rates, and its patent expires in 2037.
3/7 - Vertex has consistently grown its revenues, from $1.5 billion in 2012 when its first CF medicine was approved, to $7.6 billion in fiscal 2021, a CAGR of 14.3%.
- Cash, cash equivalents, and marketable securities of $8.2 billion as of 31 March 2022 and no debt.